ARA-290 (Cibinetide): What Human Research Shows About Neuropathy

What is ARA-290 (cibinetide)?

ARA-290, also known as cibinetide, is an investigational synthetic peptide made up of 11 amino acids. Researchers designed it from a region of erythropoietin (EPO), a naturally occurring hormone involved in red blood cell production and other biological signaling.

The research goal was to investigate tissue-protective signaling associated with EPO while limiting its stimulation of red blood cell production. That design objective does not establish that ARA-290 is safe or effective for patients. It also does not make cibinetide interchangeable with prescription EPO medicines.

Researchers have studied ARA-290 primarily in small-fiber neuropathy associated with sarcoidosis. Other research has explored diabetic macular edema and biological mechanisms related to inflammation and tissue response. These investigations remain preliminary. The studies do not establish a standard clinical use, an approved dose, or a proven treatment for nerve damage.

For readers searching for ARA-290 for neuropathy, the important distinction is this: a clinical-trial signal can justify further research, but it is not the same as an approved treatment or proof of durable benefit.

How is ARA-290 thought to work?

Scientists have proposed that cibinetide may activate a tissue-protective signaling pathway referred to in research as the innate repair receptor. This proposed receptor complex involves the erythropoietin receptor and the beta-common receptor, also known as CD131. Laboratory and animal studies have examined whether signaling through this pathway affects inflammation, cellular injury, and tissue-repair responses.

Terms such as “anti-inflammatory,” “neuroprotective,” and “nerve repair” describe the scientific questions being investigated. They should not be read as established clinical effects. A plausible mechanism in cells or animals does not prove that a peptide improves sensation, reduces pain, restores mobility, or prevents progression of neuropathy in people.

Human studies have examined measurable outcomes, including symptom questionnaires and nerve-fiber measurements in the cornea or skin. These outcomes are useful for research, but each has limits. A change in a biomarker or imaging measure does not automatically translate into a meaningful improvement a patient can feel or maintain over time.

What do human studies show about ARA-290?

The published human evidence includes a small 2012 pilot study, a 2013 subcutaneous study, a 2017 phase 2b trial, and a small 2020 study in diabetic macular edema. The trials involved different patient populations, routes, durations, and outcomes. Their results should not be combined into a claim that ARA-290 works for neuropathy generally.

2012 pilot: intravenous ARA-290 in sarcoidosis-associated small-fiber neuropathy

A 2012 randomized, double-blind pilot enrolled 22 people with sarcoidosis and symptoms of small-fiber neuropathy. Participants received either 2 mg of ARA-290 or placebo by intravenous infusion three times weekly for four weeks.

The researchers reported a greater improvement in the small-fiber neuropathy symptom-list score in the ARA-290 group than in the placebo group. Some quality-of-life measures also changed. However, the Brief Pain Inventory pain scores improved to a similar extent in both groups. The small sample, brief treatment period, and exploratory nature of the study limit the conclusions that can be drawn.

This trial is sometimes summarized online as evidence that ARA-290 “reduces neuropathic pain.” A more precise summary is that it found a difference on one symptom questionnaire in a small sarcoidosis-specific pilot, while the pain score did not differ significantly from placebo.

2013 study: subcutaneous dosing and nerve-fiber measurements

A separate 2013 randomized, placebo-controlled study evaluated daily subcutaneous ARA-290 over 28 days in people with sarcoidosis-associated small-nerve-fiber loss and neuropathic symptoms. The study enrolled 38 participants and examined symptom reports, functional measures, and nerve-fiber outcomes.

The authors reported changes in neuropathic symptoms and corneal small-nerve-fiber measurements. The study was still relatively small and short. It did not establish that any measured nerve-fiber change produced lasting functional recovery or that results would apply to other causes of small-fiber neuropathy.

It is important not to confuse the 2013 study with the earlier 22-person intravenous pilot. They were separate studies with different regimens and study designs.

2017 phase 2b trial: 64 participants and a corneal nerve-fiber endpoint

The best-known clinical study is a randomized, placebo-controlled phase 2b trial published in 2017. It included 64 people with sarcoidosis-associated small-nerve-fiber loss and neuropathic pain. Participants received placebo or 1 mg, 4 mg, or 8 mg of cibinetide by daily subcutaneous injection for 28 days.

The primary endpoint was change in corneal nerve-fiber area at day 28, measured using corneal confocal microscopy. The placebo-adjusted mean change was 697 μm² in the 4 mg group (95% confidence interval: 159 to 1,236; p = 0.012). The 1 mg and 8 mg comparisons were not statistically significant. The 4 mg group also showed an increase in a marker associated with regenerating intraepidermal nerve fibers.

These findings provide a research signal for a particular nerve-fiber measurement in a particular patient group. They do not prove that ARA-290 regrows nerves in a way that restores normal sensation, resolves neuropathy, or creates lasting improvement in everyday function. The study was short, and the measured nerve-fiber outcomes are surrogate endpoints.

Pain results need separate interpretation. Pain improved in all groups. In a subgroup with moderate-to-severe pain, the 4 mg group had a potentially meaningful placebo-adjusted pain change, but the comparison was not statistically significant (p = 0.157). The trial therefore did not conclusively establish pain relief beyond placebo.

2020 study: cibinetide for diabetic macular edema

A 2020 phase 2 pilot studied cibinetide in diabetic macular edema, an eye complication of diabetes. Nine people were recruited, and eight completed the study. Participants received 4 mg daily by subcutaneous injection for 12 weeks.

The study did not find an improvement in mean best-corrected visual acuity, central retinal thickness, central retinal sensitivity, or tear production across the group. The researchers reported an improvement in a patient-reported visual-function questionnaire and noted exploratory findings in some individuals. Because the sample was very small and the study was exploratory, those observations need confirmation in larger controlled research.

This eye study does not show that ARA-290 treats diabetic neuropathy or diabetes. A study of one complication cannot establish efficacy for a different condition.

Evidence summary

Overall, the human research is preliminary and condition-specific. It does not establish ARA-290 as a treatment for small-fiber neuropathy, chronic pain, diabetic neuropathy, autoimmune disease, or general tissue repair.

What doses have been studied, and what is known about safety?

Clinical trials have tested different routes and doses. The table below describes research protocols only. These are not prescribing instructions, a recommended dose, or a guide for self-treatment.

These trials were not designed to establish a long-term treatment plan. The optimal dose, duration, repeat-treatment schedule, and long-term safety profile remain unknown. Results from one study should not be used to choose a dose for an individual patient.

Small clinical studies can identify common short-term problems, but they cannot rule out uncommon or delayed harms. The studies also cannot answer every safety question for people with active cancer, significant organ disease, complex autoimmune conditions, pregnancy, or multiple medications.

Products sold online as “research use” materials raise additional concerns. A product label or seller-provided certificate does not by itself verify identity, purity, concentration, sterility, storage, or suitability for human use. These concerns are especially important for substances intended for injection.

Do not use online research-chemical instructions as a substitute for medical advice. New numbness, burning pain, tingling, changes in temperature sensation, weakness, or balance problems deserve appropriate clinical evaluation rather than self-treatment with an investigational peptide.

Is ARA-290 FDA-approved or eligible for compounding?

ARA-290 (cibinetide) is not an FDA-approved drug. In the FDA’s bulk drug substances document updated May 14, 2026, cibinetide appears in Category 3: substances nominated without adequate supporting information for FDA evaluation. Category 3 is not an approval or a finding that a substance is safe and effective.

FDA’s published policy states that Category 3 substances are not eligible for the interim policy that applies to Category 1 substances. FDA also says it may consider enforcement under its general policies for compounding involving these substances. The current status should be checked against FDA’s latest list and compounding guidance because agency materials can change.

HHS has published an interim enforcement-discretion policy addressing certain peptide bulk drug substances under specified conditions. Its Appendix A names BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500. Cibinetide (ARA-290) is not on that list. The policy does not make the listed peptides FDA-approved; it describes a limited enforcement policy for the substances and conditions it names.

Compounding and FDA approval are different. FDA explains that compounded drugs are not reviewed by the agency for safety, effectiveness, or quality before marketing. A research paper, online listing, or compounding discussion does not establish that ARA-290 is approved or legally available for a particular patient or use. The FDA and HHS references are listed in the Sources section below.

How should patients interpret claims about ARA-290?

When a website claims that ARA-290 “regenerates nerves,” look for the exact evidence behind the statement. Ask whether the finding came from a human clinical trial, a laboratory experiment, or an animal model. Check which condition was studied, how many people participated, how long treatment lasted, and whether the result was compared with placebo.

Next, identify what the researchers measured. Corneal confocal microscopy and skin nerve-fiber measurements can help researchers study biological changes. They are not the same as proving that patients regain protective sensation, walk farther, return to normal activities, or experience lasting pain relief.

Pay attention to statistical significance and clinical significance as separate questions. A statistically significant result can show that an observed group difference is unlikely to be due to chance under the study’s assumptions. It does not automatically mean that every participant improved or that the difference was large enough to matter in daily life.

Finally, check whether the article accurately describes the population studied. The strongest ARA-290 research discussed here concerns sarcoidosis-associated small-fiber neuropathy. It should not be generalized automatically to neuropathy related to diabetes, chemotherapy, vitamin deficiency, autoimmune disease, or an unknown cause.

For more context on the practice’s peptide information, visit the peptide therapy page. This ARA-290 research review does not state that the practice offers or recommends cibinetide.

Discussing neuropathy concerns in Stamford, Connecticut

People in Stamford and Fairfield County who have numbness, tingling, burning sensations, or nerve pain can discuss their symptoms with a qualified healthcare professional. Evaluation depends on the person’s symptoms, medical history, medications, and potential causes. This article does not diagnose neuropathy or establish that ARA-290 is appropriate for any patient.

Optimal Health Medical is located at 111 High Ridge Road in Stamford, Connecticut. Readers can review the practice’s pain treatment information or contact the office through the contact page. Call 203-348-8805 for office inquiries.

Frequently asked questions

What is ARA-290?

ARA-290, also called cibinetide, is an investigational synthetic 11-amino-acid peptide derived from a region of erythropoietin. It has been studied primarily in sarcoidosis-associated small-fiber neuropathy.

Did the 2017 trial prove that ARA-290 regenerates nerves?

No. The 2017 trial reported a statistically significant improvement in corneal nerve-fiber area in the 4 mg group and a change in a skin nerve-fiber marker. These findings do not prove lasting functional nerve recovery or establish an approved treatment.

Did ARA-290 reduce pain in the 2017 study?

Pain improved in all study groups. The placebo-adjusted pain comparison in the moderate-to-severe pain subgroup for the 4 mg group was not statistically significant (p = 0.157), so the study did not conclusively demonstrate pain relief beyond placebo.

Is ARA-290 FDA-approved?

No. ARA-290 (cibinetide) is investigational and is not an FDA-approved drug for neuropathy, pain, inflammation, or another condition.

What dose of ARA-290 should someone take?

There is no FDA-approved dose or established clinical regimen for ARA-290. Doses used in research are experimental protocols, not instructions for self-treatment.

Is ARA-290 safe for long-term use?

Long-term safety has not been established. The available human studies were limited in size and duration, so they cannot answer all questions about repeated use or safety in people with complex medical conditions.

Can ARA-290 treat diabetic neuropathy or diabetes?

Current evidence does not establish that ARA-290 treats diabetes or diabetic neuropathy. A small study in diabetic macular edema did not show improvement in its main visual-acuity outcome across the group.

Is ARA-290 included in the HHS peptide compounding policy?

No. The policy’s Appendix A lists BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500. ARA-290 (cibinetide) is not included.

What does FDA Category 3 mean for ARA-290?

FDA Category 3 identifies a substance nominated without adequate supporting information for FDA evaluation. It is not FDA approval and does not place ARA-290 in the interim policy that applies to Category 1 substances.

Are online products labeled “research use” safe to inject?

A “research use” label does not establish that a product is safe, sterile, accurately dosed, FDA-approved, or intended for human use. Do not inject an unapproved product based on online instructions.

Sources

1. Culver DA, et al. “Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain.” Investigative Ophthalmology & Visual Science. 2017.
2. Heij L, et al. “Safety and Efficacy of ARA 290 in Sarcoidosis Patients with Symptoms of Small Fiber Neuropathy: A Randomized, Double-Blind Pilot Study.” Molecular Medicine. 2012.
3. Dahan A, et al. “ARA 290 Improves Symptoms in Patients with Sarcoidosis-Associated Small Nerve Fiber Loss and Increases Corneal Nerve Fiber Density.” Molecular Medicine. 2013.
4. “A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema.” 2020.
5. FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A, updated May 14, 2026.
6. FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act.
7. HHS. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances.

Editorial note: This article is for educational purposes only. It is not medical advice, a diagnosis, or a recommendation to use an investigational product.